Cullinan治疗学击败了Q3收入估计数,尽管损失了,但分析师预测由于临床进展而升级。 Cullinan Therapeutics beat Q3 earnings estimates despite a loss, with analysts upgrading forecasts due to clinical progress.

Cullinan治疗机构报告说,2025年Q3每股损失0.77美元,击败估计数为0.18美元。 Cullinan Therapeutics reported a Q3 2025 loss of $0.77 per share, beating estimates by $0.18. HC Wainwright将其2025财政年度损失预测从4.01美元提高到3.75美元,维持了“Buy”评级和24.00美元价格目标。 HC Wainwright upgraded its FY2025 loss forecast to $3.75 from $4.01, maintaining a “Buy” rating and $24.00 price target. Wedbush将其2025财政年度预测数从4.08美元提高到3.75美元,并列举了临床进展。 Wedbush raised its FY2025 forecast to ($3.75) from ($4.08), citing clinical progress. 该公司在第一阶段试验中研制肿瘤药物,市场上限为4.3956亿美元,交易额为7.44美元,拥有强有力的机构所有权。 The company, developing oncology drugs in Phase I trials, has a market cap of $439.56 million, trades at $7.44, and has strong institutional ownership. 分析师将该股票评为"中等买入",平均目标为26.00美元. Analysts rate the stock as a “Moderate Buy” with a $26.00 average target.